Canada News Beep
  • News Beep
  • Canada
  • Headlines
  • Business
  • Entertainment
  • Health
  • Science
  • Sports
  • Technology
Canada News Beep
Canada News Beep
  • News Beep
  • Canada
  • Headlines
  • Business
  • Entertainment
  • Health
  • Science
  • Sports
  • Technology

Browsing Tag

The Company

8 posts
HHealthcare
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
Read More

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

  • September 10, 2025
BioXcel Therapeutics BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2…
CComputing
Rigetti and India’s Centre for Development of Advanced Computing Announce MOU to Explore Co-Development of Hybrid Quantum Computing Systems
Read More

Rigetti and India’s Centre for Development of Advanced Computing Announce MOU to Explore Co-Development of Hybrid Quantum Computing Systems

  • September 2, 2025
Rigetti Computing, Inc. BERKELEY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) — Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or…
HHealthcare
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
Read More

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

  • August 30, 2025
BioXcel Therapeutics BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation…
HHealthcare
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
Read More

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

  • August 26, 2025
BioXcel Therapeutics Company to host conference call at 8 a.m. ET, August 27, 2025 NEW HAVEN, Conn., Aug.…
HHealthcare
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
Read More

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

  • August 18, 2025
BioXcel Therapeutics Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home…
CComputing
Quantum Computing Inc. Reports Second Quarter 2025 Financial Results
Read More

Quantum Computing Inc. Reports Second Quarter 2025 Financial Results

  • August 14, 2025
HOBOKEN, N.J., Aug. 14, 2025 /PRNewswire/ — Quantum Computing Inc. (“QCi” or the “Company”) (Nasdaq: QUBT), an innovative, integrated…
MMedication
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
Read More

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

  • August 12, 2025
“Non-cystic fibrosis bronchiectasis deeply affects the lives of people living with this chronic lung condition, impacting both their…
MMedication
FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
Read More

FDA Grants Nutriband Meeting Request for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch

  • August 8, 2025
Nutriband Inc. FDA grants meeting for AVERSA™ FENTANYL (abuse deterrent transdermal system) to provide feedback on the Chemistry,…
Canada News Beep
www.newsbeep.com